Hormonal birth control has allowed millions worldwide to manage their menstrual cycles and control their reproductive futures ...
Blue Earth Therapeutics and University College London initiate phase 1 trial evaluating Actinium (225Ac) rhPSMA-10.1 injection in mCRPC: Oxford, UK Saturday, July 11, 2026, 16:00 ...
A look back at the most infamous, shocking, blood-curdling or mysterious true crime stories from Illinois that captured the attention of the nation — and the world.
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
A 400-participant trial found long-acting insulin glargine reduced dangerous low blood sugar and nighttime hypoglycemia in ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Anthropic’s AI-run espionage report shows why enterprises need stronger governance for AI agents, MCP connectors, and ...
Several of the products HT found on the e-commerce websites are not competing products so much as the same formulation appearing under different names.
Zacks Investment Research on MSN
NVO rallies 11% in a month: How should investors play the stock?
Novo Nordisk NVO shares have rallied 11.2% over a month as investors regained confidence in the company's obesity growth ...
The Chosun Ilbo on MSN
Invossa-K patients win first lawsuit, court cites manufacturing defect
K injection (Invossa)," a osteoarthritis treatment that was approved as South Korea’s first gene therapy but had its approval revoked after its main ingredient was found to be swapped, have won a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results